Direct answer
The CA 15-3 test is a blood test that measures cancer antigen 15-3, a protein shed by some breast cancer cells. The CA 15-3 test is used mainly to help monitor treatment response and suspected recurrence in advanced breast cancer. The CA 15-3 test cannot screen for, diagnose or exclude breast cancer.
Key takeaways
- Monitoring tool, not a diagnostic test: a breast cancer diagnosis is made by imaging and biopsy, never by CA 15-3 alone.
- Trends matter more than single values: one number in isolation tells your oncologist very little.
- A normal result is not reassurance: many breast cancers, including some metastatic ones, never raise CA 15-3.
- Benign conditions raise it: liver disease, benign breast and ovarian conditions, and some infections can raise levels.
- Reference cut-offs differ between laboratories and between assay platforms, so compare results from the same laboratory where possible.
At a glance
| Feature | Detail |
|---|---|
| Sample | Blood from an arm vein |
| Fasting | Usually not needed; follow your unit's instruction, which takes precedence |
| Time for the blood draw | Typically a few minutes; total visit time depends on queue and registration at your unit |
| Main purpose | Serial monitoring of known breast cancer, chiefly advanced or metastatic disease |
| Not used for | Population screening, first diagnosis, or excluding cancer |
| Interpreted by | The oncologist or physician who requested the test, alongside imaging and examination |
Also known as
- CA 15.3 blood test, CA 15-3 tumour marker
- Cancer antigen 15-3
- "Breast cancer marker test" or "breast tumour marker" in everyday Indian usage
- Reported on some Indian laboratory forms simply as "CA 15-3 serum"
What the CA 15-3 test is
CA 15-3 is a fragment of MUC1, a large protein found on the surface of many glandular cells. Some breast cancer cells shed MUC1 fragments into the bloodstream, and the CA 15-3 assay measures these fragments in serum. Because normal breast, lung, liver, ovarian and other glandular tissues also make MUC1, the marker is not unique to cancer.
Results are reported in U/mL. Different manufacturers' assays are not interchangeable, so a change of laboratory or platform can shift the number without any change in the disease.
Why the CA 15-3 test is done
- Tracking response to treatment in metastatic or locally advanced breast cancer, alongside imaging and clinical assessment.
- Helping assess suspected recurrence when symptoms, examination or imaging raise concern.
- Adding information when disease is hard to measure on scans, for example bone-predominant metastases.
Major guidelines do not support CA 15-3 as a routine surveillance test in people who have completed treatment for early-stage breast cancer and have no symptoms, because earlier detection of a rising marker has not been shown to improve survival and often causes anxiety and extra investigations. Your oncologist may still judge it useful in your specific situation.
Who should get this test
- Appropriate: people with known metastatic or advanced breast cancer on active treatment, where serial values help judge direction of travel.
- Sometimes appropriate: people with treated breast cancer who develop new symptoms suggesting recurrence, as one part of a wider workup.
- Not appropriate: healthy people, including those with a family history of breast cancer or a BRCA variant, as a screening test. Risk-appropriate imaging and specialist genetic counselling are the relevant pathways.
- Not appropriate: evaluating a new breast lump. A lump needs clinical examination, imaging and, if indicated, biopsy.
Men can develop breast cancer, and the same monitoring logic applies to men with a confirmed diagnosis.
What the CA 15-3 test cannot detect or exclude
- It cannot screen for breast cancer. Levels are usually normal in early, small tumours, so a normal CA 15-3 says nothing useful about whether cancer is present.
- It cannot diagnose breast cancer. Only tissue biopsy with histopathology can do that.
- It cannot exclude recurrence or metastasis. A proportion of metastatic breast cancers never produce raised CA 15-3. A normal result is a finding, not an all-clear.
- It cannot tell you where disease is. A raised value does not localise anything; imaging is needed for that.
- It cannot distinguish cancer from benign disease on its own, particularly at mildly raised levels.
- It cannot identify tumour subtype: hormone receptor, HER2 and genomic information come from tissue testing.
If symptoms such as new bone pain, breathlessness or a new lump persist despite a normal CA 15-3, go back to your doctor. A normal marker should never end an investigation that symptoms have started.
Related but different tests
| Test | Question it answers | Key difference from CA 15-3 |
|---|---|---|
| CA 27.29 | Also a MUC1-based breast cancer marker used for monitoring | Broadly similar clinical role; values are not interchangeable with CA 15-3, so stick to one marker for serial tracking |
| CEA (carcinoembryonic antigen) | Non-specific marker raised in several cancers, including some breast and colorectal cancers | Sometimes tracked with CA 15-3; smoking and benign disease also raise it |
| CA 125 | Mainly used in ovarian cancer monitoring | Different marker for a different disease; not a breast cancer test |
| Mammography, ultrasound, MRI breast | Is there a suspicious lesion, and where? | Imaging finds and localises disease; blood markers cannot |
| Core biopsy with histopathology and receptor testing | Is this cancer, and what type? | The only way to confirm diagnosis and guide treatment choice |
| CT, bone scan, PET-CT | Extent and sites of spread | Staging tools; CA 15-3 supplements but does not replace them |
| Circulating tumour DNA assays | Molecular changes in the tumour | A different technology, used for treatment selection in selected cases, not a substitute for CA 15-3 monitoring |
No single test is universally "better". Each answers a different question, and your treating team chooses based on the clinical problem in front of them.
How to prepare
- Fasting: usually not required for CA 15-3 alone. If it is bundled with lipids or glucose, fasting may be requested. Your collection unit's written instruction takes precedence.
- Bring previous reports: earlier CA 15-3 values and the laboratory name help interpretation, since assays differ.
- Tell the team about recent treatment: chemotherapy, radiotherapy, endocrine therapy or recent surgery can influence values.
- List medicines and supplements, including AYUSH preparations, herbal products and gym supplements, which can affect liver function and indirectly the marker. Do not stop any prescribed medicine for a blood test, speak to the prescriber first.
- Mention recent illness or infection, which may transiently raise the value.
If you are pregnant or breastfeeding
CA 15-3 can be raised in pregnancy and lactation, and breast tissue changes make interpretation harder. Tell the team before the sample is taken.
If you have liver or kidney disease
Chronic liver disease, cirrhosis and some renal conditions can raise CA 15-3 independently of cancer. This context needs to be on the request form.
Children and older adults
The CA 15-3 test has essentially no role in paediatric practice. In older adults, coexisting benign conditions make mildly raised values more common, so trends matter even more than single readings.
If you are on a fluid restriction or have needle anxiety
No water loading or special fluid intake is needed for this test. If you have fainted during blood tests before, ask to be drawn lying down.
What happens during the test
- Before: your identity and request form are checked, and the arm is cleaned.
- During: a tourniquet is applied and blood is drawn from a vein, usually in the forearm or elbow crease. Most draws take under five minutes.
- After: pressure is applied for a minute or two. Normal activity can resume straight away.
- If you have had axillary lymph node surgery or lymphoedema, tell the phlebotomist so the other arm can be used where possible.
Total time in the department depends on registration and queues at that facility rather than on the test itself.
Understanding your CA 15-3 report
Your report will show a value in U/mL next to the reference limit used by that specific laboratory. Cut-offs vary by assay and laboratory, so read your own report's stated range rather than a number quoted on the internet.
- Within the laboratory's reference limit: common in early disease and in many people with no cancer. This does not exclude cancer or recurrence.
- Mildly above the limit: frequently caused by benign conditions, and a single mildly raised value in isolation is usually not acted on alone. Repeat testing and clinical review are typical next steps.
- Substantially or progressively rising: may reflect increasing disease burden in someone with known breast cancer, and usually prompts imaging. It may also reflect other illness.
- Falling on treatment: may suggest response, though imaging and how you feel carry more weight.
Only the doctor who requested the test can interpret it, because interpretation depends on your stage, treatment, previous values and current symptoms. Results vary depending on individual clinical circumstances.
When CA 15-3 results can be misleading
Falsely raised or raised without cancer progression
- Chronic liver disease, cirrhosis, hepatitis including hepatitis E, and drug-induced liver injury from anti-tubercular therapy or herbal and supplement use
- Benign breast disease, endometriosis, ovarian cysts, uterine fibroids
- Pregnancy and lactation
- Autoimmune disease such as lupus or sarcoidosis
- Chronic kidney disease
- Recent infection or inflammation
- Tumour flare: a transient rise in the first weeks of starting effective chemotherapy or endocrine therapy, which can be mistaken for progression
- Laboratory interference from heterophile antibodies or high-dose biotin supplements on some platforms
Falsely reassuring or lower than expected
- Early-stage and small-volume disease, where the marker is often normal
- Tumours that do not shed MUC1, including some triple-negative and lobular cancers, which may progress with a normal marker
- A change of laboratory or assay platform, which can shift values downward and mimic improvement
Risks and safety
Venepuncture
Risks are low and mostly minor: soreness, bruising, a small haematoma, or light-headedness. Fainting is uncommon. Infection at the puncture site is rare. Bruising is more likely if you take anticoagulants or antiplatelet medicines, mention this, and press the site for longer, but do not alter the medicine.
Risks of over-testing
The more important risk with tumour markers is not the needle. Unnecessary testing in people without symptoms can produce borderline values, leading to repeated scans, added radiation exposure, cost and considerable anxiety without improving outcomes. This is why the test is targeted rather than routine.
Red flags
Emergency now
- New severe breathlessness, chest pain or coughing blood
- Sudden weakness or numbness in the legs, difficulty passing urine, or numbness around the groin and buttocks, possible spinal cord compression
- Confusion, severe persistent headache with vomiting, seizure, or a new focal weakness
- Sudden severe back or limb pain after minor injury, suggesting a fracture
Same day or urgent contact with your oncology team
- Fever above 38癈 during or soon after chemotherapy
- Persistent vomiting, inability to keep fluids down, or marked drowsiness and thirst
- Yellowing of the eyes or skin, or dark urine
- A rapidly enlarging breast or chest wall lump, skin ulceration or bleeding from the area
Routine appointment
- A rising CA 15-3 value with no symptoms, needs review, not panic
- A mildly raised result in someone without known cancer
- New persistent bone pain, unexplained weight loss, or a lasting cough over several weeks
- Questions about how often your marker should be checked
Special situations
Pregnancy and lactation
Values can be raised physiologically. Decisions in pregnancy-associated breast cancer rest on imaging and specialist assessment, not on markers.
Chronic kidney disease and heart failure
Both can be associated with non-specific marker elevation and both complicate contrast imaging that may follow a rising value. Tell the team about your kidney function and any fluid restriction before further tests are arranged.
Diabetes on glucose-lowering treatment
If fasting is requested because other tests are bundled with CA 15-3, ask your prescriber how to time your insulin or tablets, and carry a sugar source. Do not skip meals and doses unadvised.
Men with breast cancer
The test is used in the same monitoring role. Male breast cancer is uncommon, and results still require interpretation with imaging and examination.
Older adults
Benign comorbidity is common, so mildly raised values are frequent and less informative. Serial trend and symptoms guide decisions.
The CA 15-3 test in the Indian context
- Breast cancer is the commonest cancer among women in India, and Indian series consistently report a substantial proportion presenting at locally advanced or metastatic stage. Because CA 15-3 is most useful in advanced disease, the test is widely requested in Indian oncology practice.
- Misuse as a "cancer check" is common. CA 15-3 sometimes appears in self-requested health packages. It is not a screening test, and a normal value can give false comfort to someone who actually needs a clinical breast examination and appropriate imaging.
- Liver disease is a frequent confounder here. Hepatitis E, anti-tubercular therapy hepatotoxicity, and liver injury from herbal, AYUSH or gym supplements are all relevant causes of non-cancer elevation.
- Platform switching between laboratories is common when patients move between cities or hospitals. Ask for the assay name and keep all reports together for your oncologist.
- Data protection: handling of your reports and any online form is governed by the Digital Personal Data Protection Act, 2023.
Cost and insurance in India
CA 15-3 is usually priced as a single serum immunoassay, and charges differ widely between cities, laboratory chains, government facilities and private hospitals. Costs quoted anywhere should be treated as indicative only; confirm the current charge with the laboratory before the sample is taken.
- What pushes cost up: urgent or same-day processing, home sample collection, bundling with CEA or CA 125, branded or accredited laboratories, and repeat serial testing over months.
- What brings it down: testing within a hospital package during active treatment, government and trust hospital rates, and avoiding unnecessary repeat tests.
- Insurance: outpatient diagnostic tests are often not covered unless you have an OPD rider or the test is done during an admission or an approved day-care cancer treatment. Government schemes may cover oncology investigations within a defined package. Check pre-authorisation requirements with your insurer or the hospital's insurance desk.
Myths and facts
| Myth | Fact |
|---|---|
| A normal CA 15-3 means no breast cancer | Many breast cancers, especially early ones, do not raise CA 15-3. A normal result does not exclude cancer. |
| CA 15-3 can be used to screen healthy women | It is not a screening test. Guidelines do not recommend it for screening or for routine surveillance of asymptomatic early-stage survivors. |
| A raised value always means cancer has spread | Liver disease, benign gynaecological conditions, pregnancy, infection and lab interference can all raise it. |
| A high number means severe disease | The absolute number correlates only loosely with disease burden. Trend plus imaging matter more. |
| CA 15-3 can replace scans | Only imaging can show where disease is and how it is behaving anatomically. |
| Results from any two laboratories can be compared directly | Assays differ between platforms; serial monitoring should ideally use the same laboratory. |
Frequently asked questions
Can the CA 15-3 test diagnose breast cancer?
No. The CA 15-3 test cannot diagnose or exclude breast cancer. Diagnosis needs clinical examination, imaging such as mammography or ultrasound, and a core biopsy examined by a pathologist. CA 15-3 is used mainly to follow disease that has already been confirmed, usually advanced breast cancer.
My CA 15-3 is slightly above the reference limit. Should I be worried?
A single mildly raised value is often not due to cancer. Liver disease, benign breast or ovarian conditions, pregnancy, recent infection and assay interference all cause small elevations. Your doctor will consider your history, examine you, and may repeat the test after an interval before ordering any imaging.
Why did my marker rise just after starting chemotherapy?
A temporary rise in the early weeks of effective treatment, sometimes called tumour flare or spike, is recognised with markers such as CA 15-3. It can be mistaken for worsening disease. Your oncologist will usually repeat the test later and rely on imaging and symptoms rather than one value.
How often should the CA 15-3 test be repeated?
Frequency depends on your stage, treatment and previous values, and is decided by your oncologist. In metastatic disease it is often checked alongside treatment cycles or imaging. For people who have finished treatment for early-stage cancer and feel well, routine repeat marker testing is generally not recommended.
Do I need to fast before a CA 15-3 test?
Fasting is usually not required for CA 15-3 alone. If the sample is being taken along with fasting tests such as glucose or lipids, your unit may ask you to fast. Follow the written instruction given by your collection centre, as unit protocols differ.
What is the difference between CA 15-3 and CA 27.29?
Both detect fragments of the same MUC1 protein and have a similar clinical role in monitoring breast cancer. The assays are built differently, so values are not interchangeable. Your team will pick one and track it consistently. Switching between them mid-treatment makes the trend difficult to interpret.
Can men have this test?
Yes. Men do develop breast cancer, and the CA 15-3 test can be used in the same monitoring role after diagnosis. As in women, a raised result needs interpretation with imaging and examination, and benign causes such as liver disease must be considered before assuming cancer activity.
Can infections or supplements change my result?
Yes. Recent infection and inflammation can raise CA 15-3 temporarily. High-dose biotin supplements can interfere with some immunoassay platforms, and liver injury from herbal, AYUSH or gym supplements can raise the marker indirectly. Tell your doctor about recent illness and everything you are taking, including non-prescription products.
How long does the whole process take?
The blood draw itself usually takes only a few minutes, and you can resume normal activities straight away. Total time at the facility depends on registration and queues. Reporting time varies between laboratories and depends on whether samples are run in batches or sent to a referral laboratory.
Sources
- American Society of Clinical Oncology guidance on the use of biomarkers in metastatic and early-stage breast cancer [Confirm current edition, TO BE VERIFIED]
- European Group on Tumour Markers recommendations on breast cancer biomarkers [Confirm current edition, TO BE VERIFIED]
- National Cancer Institute, patient information on tumour markers
- Indian Council of Medical Research - National Centre for Disease Informatics and Research, National Cancer Registry Programme reports on breast cancer incidence and stage at presentation [Confirm current edition, TO BE VERIFIED]
- Assay manufacturer package inserts for CA 15-3 immunoassays, for platform-specific reference limits and interference data
